Réforme de l'accès dérogatoire aux médicaments (MAJ 24/04/23) - OMEDIT Ile de France
THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) • The Journal of Prevention of Alzheimer's Disease
Full article: A comparative public health and budget impact analysis of pneumococcal vaccines: The French case
Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France | PLOS ONE
Hepatitis B or Delta liver transplant patients at risk of recurrence: Long-term effectiveness and budget impact of low-dose subcutaneous anti-hepatitis B immunoglobulin plus patient education program - ScienceDirect
Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France | PLOS ONE
Modèle tarifaire équitable | Zur Rose
PDF) Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: Results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)
THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) • The Journal of Prevention of Alzheimer's Disease
THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) • The Journal of Prevention of Alzheimer's Disease
Prix des médicaments - Comparaison avec l'étranger 2011, Conférence de presse santésuisse, interpharma et vips 20
POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure | SpringerLink
PDF) Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France
Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France - Erin Johansson, Anders Gustavsson, Carolin Miltenburger, Korinna Karampampa, Lucien Rumbach, Karin Rérat, Celine Thonnelier, 2012
utilisation des médicaments dans les maisons de soins - KCE
La libre fixation des prix des médicaments financés dans les groupes homogènes de séjour hospitalier : une exception au régime des prix administrés des médicaments à conserver ? | Cairn.info
Competition From Biosimilars Drives Price Reductions For Biologics In The French Single-Payer Health System | Health Affairs
PDF) The economic burden of urinary tract infections in women visiting general practices in France: A cross-sectional survey
Vaccines | Free Full-Text | Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer
La base de données médicaments Thériaque - CNHIM
Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France | PLOS ONE
Supplementary materials Methods Calculation of costs and HCRU A cost of €24.13, which included official tariffs and surcharges
8 remèdes au prix élevé des médicaments | Paperjam News
Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France | PLOS ONE
